Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24



19310 items
5:55 PM, Jun 22, 2018  |  BioCentury | Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...
5:51 PM, Jun 22, 2018  |  BioCentury | Strategy

Gawande’s Cheesecake Factory

Details about the healthcare organization Atul Gawande will run for Inc., Berkshire Hathaway Inc. and J. P. Morgan Chase & Co. are scarce -- basic facts, starting with its name, have not been disclosed....
5:15 PM, Jun 22, 2018  |  BioCentury | Regulation

Emergency preparedness

Borrowing a page from the software industry, FDA Commissioner Scott Gottlieb believes that licensing rather than selling certain antibiotics could help address the crisis of multidrug resistant pathogens. He is hoping to work with CMS...
1:59 PM, Jun 22, 2018  |  BioCentury | Finance

Bountiful, not bubbly

A compressed calendar, rather than investor overexuberance, accounts for one of the busiest weeks for IPO pricings in the sector’s history. Seven NASDAQ IPOs were completed during the week ending June 22, raising a total of...
1:58 PM, Jun 22, 2018  |  BioCentury | Finance

Direct from UCB Ventures

UCB Ventures’ recent investment in Durham, N.C.-based gene therapy play StrideBio Inc. marks the next phase in how the strategic investor plans to deploy its €150 million ($174 million) fund. After backing multiple healthcare VC...
5:05 AM, Jun 22, 2018  |  BioCentury | Finance

Regenerating eastward

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators. After...
7:35 PM, Jun 19, 2018  |  BioCentury | Strategy

Channel your outrage

Before the dust settles on the PABNAB debacle, save some outrage for what really matters: not the periodic stripper party that screams “sickening,” but the entrenched attitudes and daily affronts that end up keeping women...
6:38 PM, Jun 19, 2018  |  BioCentury | Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
8:35 PM, Jun 15, 2018  |  BioCentury | Product Development

MATCH’s long game

Although three of the first four arms in NCI-MATCH missed their endpoints, the results suggest the basket trial is doing what it is supposed to -- finding efficacy signals in rare cancers. It’s also yielded...
6:12 PM, Jun 15, 2018  |  BioCentury | Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and a...